Tolvaptan success in rare kidney disease
This article was originally published in Scrip
Executive Summary
Otsuka’s vasopressin V2 receptor antagonist tolvaptan has met the primary endpoint in a Phase III trial in patients with autosomal dominant polycystic kidney disease (ADPKD), providing a strong basis for global regulatory filings in this additional indication, the company says.